Counterfeit Wegovy and Ozempic: How to Tell If Yours Is Real in 2026

In June 2024, the WHO issued Medical Product Alert N°2/2024 — its first global alert on falsified semaglutide — after fake Ozempic batches turned up in pharmacy supply chains in Brazil, the UK, and the US. The agency doesn't reach for that lever often. By the time it does, the same product has usually been moving through more than one continent's distribution system for months, sometimes longer. A WHO alert is the smoke, not the spark.

The stretch from 2024 through 2026 has produced one of the busiest enforcement runs in modern injectable drug history. The FDA flagged counterfeit Ozempic twice in 2023 — a single fake pen surfaced at a US retail pharmacy in June, then a much larger seizure followed in December — and more batches turned up across multiple states through 2024 and 2025, some covering thousands of units. The MHRA in the UK, BfArM in Germany, and FAMHP in Belgium have all issued falsified semaglutide notices. Singapore's HSA has run multiple advisories. Hong Kong's Drug Office has hospitalized patients who injected pens containing no semaglutide at all. Korea's MFDS banned overseas direct purchase of GLP-1s outright in October 2024. Japan's PMDA is tracking imported semaglutide for off-label cosmetic use as a growing problem. China's NMPA has prosecuted illegal manufacturers. Saudi SFDA and UAE MOHAP have launched public-awareness campaigns.

If you have a Wegovy, Ozempic, Mounjaro, Zepbound, Saxenda, or local-brand GLP-1 in your refrigerator right now — mine is sitting on the second shelf next to the leftover takeout — the question isn't whether counterfeits exist. They do, in volume. The real question is narrower and more personal: is the specific box in front of you one of them, and can you tell before you press the button on a pen that might be filled with insulin, saline, or contaminated tap water?

What the regulators have actually done since 2023

The pattern is consistent across agencies. Counterfeit pens slip into the legitimate wholesale chain — usually through one grey-market distributor or a stolen-and-resold lot — and then surface at retail pharmacies that had no reason to suspect them.

The FDA's first counterfeit Ozempic case came in June 2023, when a single fake pen — later found to contain insulin glargine rather than semaglutide — turned up at a US retail pharmacy. The bigger event came in December 2023: working with Novo Nordisk, the agency seized thousands of units of counterfeit Ozempic 1 mg pens from the US supply chain. Through 2024 and into 2025, additional batches were found, some testing positive for bacterial contamination — a sterility failure that turns a routine injection into a sepsis risk.

WHO's June 2024 alert formalized what national agencies were already chasing. Three confirmed countries at announcement (Brazil, UK, US), with the agency strongly implying the actual list was longer. The alert specifically warned that some falsified products had been "lawfully obtained from authorised suppliers" downstream of the breach point. Translation: the pharmacist did not know.

A short timeline of regulatory action since 2023:

• June 2023 — first counterfeit Ozempic pen found at a US retail pharmacy (later identified as insulin glargine).
• December 2023 — FDA seizes thousands of counterfeit Ozempic units, multi-state distribution.
• Throughout 2023–2024 — MHRA (UK), BfArM (Germany), FAMHP (Belgium) issue national falsified-semaglutide alerts.
• June 2024 — WHO Medical Product Alert N°2/2024 published.
• 2024 — Singapore HSA runs multiple counterfeit GLP-1 advisories.
• 2024 — Hong Kong Drug Office seizes "Ozempic" pens with zero semaglutide content; hospital admissions reported.
• October 2024 — Korea MFDS bans overseas direct purchase of GLP-1 medications.
• 2024–2025 — China NMPA prosecutes multiple illegal semaglutide manufacturers.
• 2024–2025 — Brazil ANVISA expands counterfeit Ozempic warnings.
• 2024–2025 — Saudi SFDA and UAE MOHAP launch consumer awareness campaigns on counterfeit Ozempic, Saxenda and Wegovy.
• 2024–2026 — Japan PMDA flags rising imports of semaglutide for off-label cosmetic weight loss.

The throughline: counterfeiters target whatever brand has the longest pharmacy queue. In 2023 that was Ozempic. By 2024 it was Wegovy. Mounjaro and Zepbound joined the target list as soon as US allocation tightened. The molecule changes; the playbook does not.

WHO Alert N°2/2024 was the first global flag, but it was not the first event. National agencies had been tracking grey-market semaglutide for at least nine months before WHO formalized the warning. If your pharmacy is downstream of a wholesaler who was not paying attention in 2023, the question is what else got through.

Country and region matrix — what is approved, what is being faked, what to look up

Brand names matter because counterfeiters copy whatever box your country actually stocks. A fake "Ozempic" box in a market where the legitimate product ships as 诺和泰 is a near-instant tell — the forger reached for the wrong label. A Wegovy box in a country where Wegovy hasn't officially launched yet is the same mistake from the other direction.

Two things jump out of that table. The countries leaning hardest on enforcement — US, UK, Germany, Korea, Singapore — are the same ones where legitimate supply ran tightest in 2023–2024. That's not a coincidence: a shortage is the demand vacuum a counterfeiter rushes to fill. And every market on the list already has a national lookup tool. Almost no patient ever opens one.

How to verify the prescription in your hand is real

This isn't about inspecting every pen like a forensic lab. It's a five-minute checklist before you inject — the kind of thing you run once on a Sunday until it lives in muscle memory. Counterfeit pens are sometimes obvious, sometimes nearly perfect, but they almost always fail at least one of the checks below.

Start at the box, then the pen, then the supply chain.

Box-level checks (Novo Nordisk products: Ozempic, Wegovy, Saxenda)

1. Holographic foil panel on the side of the carton. Tilts and shifts when you angle the box. Counterfeit boxes often print a flat metallic ink that does not move under light.
2. Lot number printed on the carton. Matches the lot number on the pen itself. Both should look up cleanly on novocare.com (US) or the local Novo verification page.
3. Spelling. "Ozempic," "Wegovy," "semaglutide." A missing letter, a swapped O for a 0, or a doubled consonant is the most common counterfeit tell still in circulation.
4. Country-specific language and package insert. A box claiming to be Korean Wegovy should have Korean text on the carton and a Korean PIL inside. An English-only box sold in Seoul is a red flag regardless of where you bought it.
5. Manufacture and expiry dates printed cleanly, not over-stamped or smudged.

Box-level checks (Eli Lilly products: Mounjaro, Zepbound)

1. Single-dose pen format with a date and lot stamped on each individual pen. Counterfeit Mounjaro has been observed with mismatched lot numbers between the carton and individual pens.
2. Lot number lookup at lillyserialnumberlookup.com (US). Other markets have country-specific Lilly verification — your pharmacist can show you which.
3. Tamper-evident carton seal intact. Lilly cartons use a perforated tab. A clean, glued reseal is suspicious.

Pen-level checks (all GLP-1 injectors)

1. Clear cartridge with a visible solution. Real semaglutide and tirzepatide are clear, colorless to slightly yellow, and free of particles. Cloudy, turbid, off-white, or particle-containing solution should never be injected.
2. Pen mechanism feels firm, not loose. The dose dial clicks into discrete steps.
3. Label printed directly on the pen, not stickered on. A label that peels at the corner is a counterfeit fingerprint.
4. Needle attachment threading is consistent and the pen accepts the standard pen-needle for that brand.

Pharmacy and supply-chain checks

1. Bought from a state-licensed pharmacy. In the US, the NABP Verified Pharmacy site (safe.pharmacy) lists legitimate online sellers. In Korea, your prescription must be filled at a 약국. In the UK, GPhC-registered pharmacies only.
2. Real prescription required. This is the single biggest sorting filter. Any seller offering Wegovy, Ozempic, Mounjaro or Zepbound without a current prescription from a licensed prescriber is selling either a counterfeit or a stolen legitimate pen — neither is safe.
3. Price sanity check. US list price for Ozempic is roughly $970 per month; Wegovy's list price is roughly $1,350 per month. Mounjaro and Zepbound run roughly $1,000 to $1,300. Anything offered below about $200 a month outside Lilly Direct or NovoCare is a red flag, full stop. Coupons, manufacturer assistance and insurance can lower your out-of-pocket cost, but that lower price should come through a verifiable program, not a Telegram channel.
4. Cold-chain intact. GLP-1s ship and store at 2–8°C. A box arriving warm, or stored at room temperature for more than the manufacturer-permitted window, is a quality failure even if the contents are authentic.

A practical pre-injection checklist:

• Bought from a pharmacy licensed in my country.
• A licensed prescriber wrote the script.
• Cold chain held throughout shipping and storage.
• Carton tamper seal intact, no signs of resealing.
• Brand name and country language match what is approved in my market.
• Lot number on carton matches lot number on the pen.
• Lot number verifies on the manufacturer's lookup tool.
• Solution in the cartridge is clear and free of particles.
• Holographic foil (Novo) shifts under angle, label is printed not stickered (Lilly).
• Price paid is consistent with a legitimate pharmacy or manufacturer program.

Nine out of ten genuine prescriptions clear all ten boxes without a hitch. A counterfeit fails at least one — often three or four. The five-minute audit isn't overcautious. It's the line between an injection that loses you weight and an injection that ships you to the emergency department. I run mine standing at the kitchen counter, box in one hand, phone in the other. Two minutes, every refill.

Where the official lookup tools live, by agency

Half the work is just knowing where to click. A patient who knows where to verify a lot number spends about three minutes on it. A patient who doesn't shrugs and injects anyway. That gap — three minutes versus a shrug — is most of the risk.

The regional tools differ but the underlying logic is identical. Every legitimate GLP-1 sold under a brand name has a registered SKU, a manufacturer-issued lot number, and a licensed pharmacy chain behind it. Every counterfeit fails on at least one of those three. The lookup tools exist for the patient to confirm — they were never designed for pharmacists alone.

Questions worth asking your doctor or pharmacist

Pharmacists know more about supply-chain integrity than almost anyone else in the system. They are also rarely asked about it directly. A few prompts that change the conversation:

• "Where does this specific pen come from in your wholesale chain?" Most legitimate US pharmacies source through one of three big wholesalers (McKesson, Cardinal Health, AmerisourceBergen) — and the pharmacist can name the chain. A vague answer is itself information.
• "Have any falsified semaglutide or tirzepatide alerts been issued in our country in the past 12 months?" Your pharmacist should know. If they do not, the pharmacy is not paying attention to the FDA / EMA / MHRA alert feeds it should be reading.
• "If I find a discrepancy on the lot number lookup, who do I report it to?" The answer should be specific — manufacturer hotline, national agency MedWatch or Yellow Card equivalent, and a return path to the pharmacy.
• "Is this a Medicare or insurance fill, a cash-pay fill from a manufacturer DTC program, or a cash-pay fill from another channel?" The first two are documented. The third needs to be a pharmacy you trust.
• "What does the pen look like if I open the box right now and you walk me through it?" A pharmacist who agrees to do this on the spot is the gold standard. One who refuses, or rushes you out the door, is worth a second thought.

For doctors specifically:

• "If supply tightens, do you have a verified-source backup channel — manufacturer DTC, hospital pharmacy, integrated health-system pharmacy?" The grey-market patients are usually the ones whose primary pharmacy ran out and who were left to improvise.
• "Will you write me a 90-day script if my insurance allows it, so I am not refilling monthly through whatever channel happens to be open?" Fewer refill events means fewer counterfeit-exposure events.

In the 2024 Hong Kong hospital-admission cases, the through-line was the same: the patients did not ask where the pen came from. They asked the price and they asked the dose. Nobody asked the supply chain question.

What to check before you buy or refill

If you are reading this before your next refill — that is the right time to use this. After the injection is too late.

For US patients:

1. Confirm your prescription source. State-licensed retail pharmacy, hospital pharmacy, manufacturer DTC (NovoCare, LillyDirect), or a NABP-Verified online pharmacy. If your seller is none of those four, stop.
2. Run the lot number on novocare.com (Novo products) or lillyserialnumberlookup.com (Lilly products) when the box arrives.
3. Cross-check pricing. Ozempic's US list price is around $970/month and Wegovy's around $1,350/month before insurance. Mounjaro and Zepbound run $1,000–$1,300. Manufacturer cash-pay programs (LillyDirect Zepbound starting at $349/month for boxed vials, NovoCare cash-pay options) sit in a defined band. Anything well below requires explanation.
4. Check the FDA drug shortage database. Tirzepatide came off the shortage list in December 2024; semaglutide came off in February 2025. Re-listing would be the earliest public signal that supply is tight again — and tight supply is when counterfeiters move volume.

For UK and EU patients:

1. Pharmacy must be GPhC-registered (UK), or the equivalent national pharmacy regulator across EU member states. Check the register before you buy.
2. Distance-selling pharmacies are legal but must display the EU common logo and link to the national regulator's verified-list page. No logo or no link means stop.
3. MHRA Yellow Card scheme accepts reports of suspected falsified medicines. National equivalents exist across the EU. File the report — it is what triggers the next national alert.

For patients in Korea, Japan and Hong Kong:

1. Korea: prescription only, dispensed at a 약국, and as of October 2024 overseas direct purchase (직구) of GLP-1 medications is banned outright. Anything bought through 직구 since that date is illegal regardless of authenticity, and customs has been seizing shipments at the border.
2. Japan: PMDA has flagged a rise in semaglutide imported for off-label cosmetic weight loss. If a Tokyo or Osaka clinic is offering ウゴービ or generic semaglutide without a documented obesity workup and PMDA-approved indication, the supply chain is a question mark.
3. Hong Kong: Drug Office issues prescription-medicine notices through the Department of Health. The 2024 hospital-admission cases involved unlicensed beauty centres dispensing fake "Ozempic." Licensed pharmacy plus a doctor's prescription remains the only safe route.

For patients in the Gulf:

1. Saudi Arabia: SFDA's Tatamman app verifies registered medicines by scanning the box. Use it. UAE has equivalent verification through MOHAP and the Dubai Health Authority.
2. Cash-pay private clinics are common across the region; the regulated ones operate inside licensed pharmacy channels. The unregulated ones often do not.
3. Distributor allocation lags global decisions by roughly a quarter. If the US tightens, Gulf shelves usually feel it 60 to 90 days later — which is also when grey-market substitutions tend to appear.

For patients in mainland China:

1. The legitimate brands are 诺和盈 (Wegovy), 诺和泰 (Ozempic) and 穆峰达 (Mounjaro). English-language packaging sold inside mainland China is a near-automatic counterfeit flag.
2. NMPA's drug-verification portal accepts the unique identifier on each box.
3. Hospital pharmacy is the safest channel; community pharmacies vary by region in how aggressively they vet wholesalers.

What this looks like in your market today

Here's how the ground looks market by market, as of April 2026:

United States. Counterfeit Ozempic remains the highest-volume confirmed threat. FDA alerts in 2023 and 2024 named specific lot numbers, but the scale of the parallel grey market means new fakes will keep surfacing. Wegovy and Zepbound counterfeits are a smaller but growing share. Lilly Direct's $349/month boxed-vial Zepbound program has materially reduced the cash-pay incentive to shop grey. NovoCare cash-pay options are similar. If you have a path to a manufacturer DTC program, it is the cleanest signal-to-noise channel available.

United Kingdom and EU. The MHRA, BfArM, FAMHP cluster of 2023–2024 alerts is the warning signal. NHS-channel Wegovy is essentially counterfeit-free; the risk concentrates in private slimming clinics that import from outside the EU GMP chain. The EU common logo on online pharmacy sites is a hard requirement, not a suggestion.

Korea. The October 2024 ban on 직구 of GLP-1s was the single biggest regulatory change for Korean patients in this cycle. It moved supply almost entirely back into the licensed 약국 channel. The remaining counterfeit risk concentrates in social-media private sellers and a small number of unlicensed cosmetic clinics. Mounjaro received MFDS obesity approval in July 2024, but supply has been tight since the August 2025 launch — which historically is when grey-market substitution accelerates. Stay in the licensed channel.

Japan. Cosmetic-clinic semaglutide is the watch-list segment. The legitimate ウゴービ pathway through PMDA-registered endocrinology and obesity clinics is intact; the import-and-inject cosmetic clinic segment is where PMDA advisories have concentrated through 2024–2026.

Hong Kong and Singapore. Both regulators have been aggressive — multiple counterfeit advisories from HSA, hospital admissions documented in HK. The licensed-pharmacy plus prescription path remains the only one that consistently clears. Beauty-centre dispensing is the avoidable failure mode.

Saudi Arabia and UAE. Public-awareness campaigns from SFDA and MOHAP through 2024–2025 reflect the volume of grey-market product surfacing in private cash-pay channels. Tatamman (Saudi) and the MOHAP licensed-pharmacy registry (UAE) are the practical verification tools. Use them at the pharmacy counter, not after you get home.

China mainland. NMPA prosecutions have hit the supply side of the counterfeit market. The patient-facing risk concentrates in English-packaged "Ozempic" sold through informal channels — usually a near-automatic counterfeit. The 诺和盈 / 诺和泰 / 穆峰达 SKUs through hospital pharmacy are the safe path.

Brazil. ANVISA warnings continued through 2024 after Brazil was named as a source country in WHO Alert N°2/2024. Hospital and licensed-farmácia channels are the way through; informal resellers shipping from neighbouring countries remain a documented risk.

If you want context on how shortages and grey-market activity track each other, our Medicare Wegovy global ripple breakdown walks the supply-allocation mechanics that drive the counterfeit market in the first place. Our big-pharma DTC access piece covers the manufacturer cash-pay channels — NovoCare and LillyDirect — that have done more to undercut counterfeit demand than any single enforcement action. And if you are weighing whether the side effects you are seeing on a refilled pen are normal versus a quality-control issue, the Wegovy side effects guide and the Mounjaro side effects guide are the side-effect baselines to compare against.

The five-minute kitchen-counter audit — license, prescription, lot number, cold chain, label, solution, price — isn't paranoia. It's the lowest-effort patient-safety move available to you right now, and it costs you a coffee's worth of attention. None of it replaces a conversation with your prescribing clinician or pharmacist. It's the homework worth doing before that conversation, not after it. The next refill is the right moment to start. The pen already sitting in your fridge tonight is the better one.

This article is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. All GLP-1 medications discussed are prescription drugs — do not start, stop, or change any medication without consulting your doctor. Individual results vary. For the most current prescribing information, refer to the FDA-approved labeling for each drug.

Start managing your GLP-1 with Blueshot

AI coaching, injection scheduling, and weight tracking in one app